New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful ...

The National Institutes of Health plans to launch a public-private partnership in December to speed development of personalized cancer vaccines, according ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease ...

The market dynamics for Epstein-Barr virus (EBV) are evolving, driven by the high prevalence of infection worldwide, the growing recognition of EBV-associated malignancies and other complications, and ...

Saudi Arabia's flagship biotech gathering is no longer a regional talking shop. The Riyadh Global Medical Biotechnology Summit closed its ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical ...

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and ...

Distinct profiles between mild and severe COVID-19 patients reveal why some fight off infection easily while others don't, guiding the development of mutation-resistant vaccines.